|
gptkbp:instanceOf
|
gptkb:chemical_compound
antiviral drug
antineoplastic agent
|
|
gptkbp:administeredBy
|
intravenous infusion
|
|
gptkbp:approvalYear
|
1996
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
L01BC05
|
|
gptkbp:bioavailability
|
not orally bioavailable
|
|
gptkbp:brand
|
gptkb:Gemzar
|
|
gptkbp:CASNumber
|
95058-81-4
|
|
gptkbp:category
|
World Health Organization essential medicine
|
|
gptkbp:chemicalFormula
|
C9H11F2N3O4
|
|
gptkbp:combinationTherapy
|
gptkb:carboplatin
gptkb:cisplatin
paclitaxel
|
|
gptkbp:contraindication
|
hypersensitivity to gemcitabine
|
|
gptkbp:developedBy
|
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:discoveredBy
|
1983
|
|
gptkbp:eliminationHalfLife
|
42–94 minutes
|
|
gptkbp:excretion
|
gptkb:kidney
|
|
gptkbp:first_clinical_use
|
1990s
|
|
gptkbp:hasSMILES
|
C1=CN(C(=O)NC1=O)[C@H]2C(C(C(O2)CO)O)(F)F
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Gemcitabine
|
|
gptkbp:IUPACName
|
4-amino-1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
|
|
gptkbp:KEGGID
|
gptkb:D00521
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits DNA synthesis
|
|
gptkbp:metabolism
|
gptkb:cytidine_deaminase
|
|
gptkbp:molecularWeight
|
263.2 g/mol
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL1637
gptkb:DB00441
60750
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
fever
nausea
vomiting
rash
elevated liver enzymes
myelosuppression
|
|
gptkbp:synonym
|
gptkb:2',2'-difluorodeoxycytidine
|
|
gptkbp:UNII
|
G3UV8Q2FSX
|
|
gptkbp:usedFor
|
gptkb:non-small_cell_lung_cancer
gptkb:cancer
pancreatic cancer
bladder cancer
|
|
gptkbp:bfsParent
|
gptkb:Non-Small_Cell_Lung_Cancer
|
|
gptkbp:bfsLayer
|
6
|